EP0671951A4 - Humanized antibodies reactive with l-selectin. - Google Patents

Humanized antibodies reactive with l-selectin.

Info

Publication number
EP0671951A4
EP0671951A4 EP94903357A EP94903357A EP0671951A4 EP 0671951 A4 EP0671951 A4 EP 0671951A4 EP 94903357 A EP94903357 A EP 94903357A EP 94903357 A EP94903357 A EP 94903357A EP 0671951 A4 EP0671951 A4 EP 0671951A4
Authority
EP
European Patent Office
Prior art keywords
selectin
humanized antibodies
antibodies reactive
reactive
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94903357A
Other languages
German (de)
French (fr)
Other versions
EP0671951A1 (en
Inventor
Man Sung Co
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of EP0671951A1 publication Critical patent/EP0671951A1/en
Publication of EP0671951A4 publication Critical patent/EP0671951A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP94903357A 1992-12-01 1993-11-30 Humanized antibodies reactive with l-selectin. Withdrawn EP0671951A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98394692A 1992-12-01 1992-12-01
US983946 1992-12-01
PCT/US1993/011612 WO1994012215A1 (en) 1992-12-01 1993-11-30 Humanized antibodies reactive with l-selectin

Publications (2)

Publication Number Publication Date
EP0671951A1 EP0671951A1 (en) 1995-09-20
EP0671951A4 true EP0671951A4 (en) 1997-05-21

Family

ID=25530200

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94903357A Withdrawn EP0671951A4 (en) 1992-12-01 1993-11-30 Humanized antibodies reactive with l-selectin.

Country Status (12)

Country Link
EP (1) EP0671951A4 (en)
JP (1) JPH08503617A (en)
KR (1) KR100371784B1 (en)
AU (1) AU689090B2 (en)
CA (1) CA2149025A1 (en)
CZ (1) CZ140195A3 (en)
FI (1) FI952658A (en)
HU (1) HUT71790A (en)
NO (1) NO952160L (en)
PL (1) PL309249A1 (en)
RU (1) RU2151612C1 (en)
WO (1) WO1994012215A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
WO1996040942A1 (en) * 1995-06-07 1996-12-19 Cytel Corporation Humanized antibodies to e-selectin
WO1997006822A1 (en) * 1995-08-17 1997-02-27 Protein Design Labs, Inc. Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage
AU746888B2 (en) * 1995-08-17 2002-05-02 Protein Design Labs, Inc. Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
CA2266640C (en) * 1996-09-27 2011-05-24 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
EP0852951A1 (en) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
WO1999043353A2 (en) * 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
US20020029391A1 (en) * 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
UY28886A1 (en) * 2004-05-10 2005-12-30 Boehringer Ingelheim Int ANTIBODIES CONSISTING IN POLYPEPTIDES AND DERIVATIVES UNDERSTANDING THREE SEQUENCES CONCERNING THE FOLLOWING NUMBERS OF SEQ. ID: 1-3 AND 4-6; 7-9 AND 10-12 AND 13-15 OR 16-18
JP5624276B2 (en) 2006-03-31 2014-11-12 中外製薬株式会社 Methods for controlling blood kinetics of antibodies
RU2511406C2 (en) 2006-06-08 2014-04-10 Чугаи Сейяку Кабусики Кайся Preventive and therapeutic agent for inflammatory disease
EP4368721A2 (en) 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
AR068563A1 (en) 2007-09-26 2009-11-18 Chugai Pharmaceutical Co Ltd CONSTANT MUTANT ANTIBODY REGION
EP2241332A4 (en) 2007-12-05 2011-01-26 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
DK2236604T3 (en) 2007-12-05 2016-10-03 Chugai Pharmaceutical Co Ltd The anti-NR10 antibody and use thereof
MY195714A (en) 2008-04-11 2023-02-07 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable of Binding to Two or More Antigen Molecules Repeatedly
KR20160062207A (en) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 Anti-NR10 antibody and use thereof
JP2010210772A (en) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd Method of manufacturing liquid crystal display device
TWI544077B (en) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
CA2806233C (en) * 2010-07-26 2021-12-07 Trianni, Inc. Transgenic animals and methods of use
EP3960865A1 (en) 2010-08-02 2022-03-02 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
KR102385507B1 (en) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2012088265A1 (en) * 2010-12-21 2012-06-28 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification
IN2013CN07629A (en) 2011-02-25 2015-08-07 Regeneron Pharma
RU2664232C2 (en) 2011-08-05 2018-08-15 Регенерон Фармасьютикалз, Инк. Humanised universal light chain mice
EP3527070A1 (en) 2011-12-20 2019-08-21 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
US10238093B2 (en) 2012-06-12 2019-03-26 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
KR20230158661A (en) 2014-03-21 2023-11-21 리제너론 파마슈티칼스 인코포레이티드 Non-human animals that make single domain binding proteins
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
AU2016232715A1 (en) 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
KR20170134748A (en) 2015-04-14 2017-12-06 추가이 세이야쿠 가부시키가이샤 A medicament composition for preventing and / or treating atopic dermatitis containing IL-31 antagonist as an active ingredient
BR112022006590A2 (en) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd PREPARATION CONTAINING ANTIBODIES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011018A1 (en) * 1990-12-19 1992-07-09 Protein Design Labs, Inc. Improved humanized immunoglobulins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011018A1 (en) * 1990-12-19 1992-07-09 Protein Design Labs, Inc. Improved humanized immunoglobulins

Also Published As

Publication number Publication date
CA2149025A1 (en) 1994-06-09
FI952658A0 (en) 1995-05-31
AU689090B2 (en) 1998-03-26
AU5732794A (en) 1994-06-22
NO952160L (en) 1995-07-31
PL309249A1 (en) 1995-10-02
EP0671951A1 (en) 1995-09-20
RU2151612C1 (en) 2000-06-27
WO1994012215A1 (en) 1994-06-09
KR100371784B1 (en) 2003-07-22
HUT71790A (en) 1996-02-28
NO952160D0 (en) 1995-05-31
FI952658A (en) 1995-05-31
HU9501564D0 (en) 1995-07-28
JPH08503617A (en) 1996-04-23
CZ140195A3 (en) 1996-06-12

Similar Documents

Publication Publication Date Title
EP0671951A4 (en) Humanized antibodies reactive with l-selectin.
AU4025193A (en) Humanized C-erbB-2 specific antibodies
IL111926A0 (en) Humanized antibodies and uses thereof
AU4618193A (en) Humanized antibodies
EP0627932A4 (en) Novel antibody construct.
EP0604033A3 (en) Sealing arrangements.
EP0676966A4 (en) Antibodies directed against binding-associated epitopes.
AU5732694A (en) Humanized antibodies reactive with cd18
EP0578515A3 (en) Humanized monoclonal antibodies.
GB9412166D0 (en) Retargetting antibodies
GB9313288D0 (en) The super bottle
EP0580859A4 (en) Anti-eda monoclonal antibody
EP0506523A3 (en) Monoclonal antibodies
GB2246827B (en) Pipe stopper
EP0654532A4 (en) Antimucoglycoprotein monoclonal antibody.
EP0640621A3 (en) Anti-thrombin monoclonal antibody.
EP0671924A4 (en) Digitalis-like compounds.
ZA931100B (en) A 90K tumor-associated antigen, IR-95.
EP0597211A3 (en) Optical duplexer.
ZA912136B (en) Anti-oncostatin m monoclonal antibodies
EP0668923A4 (en) Monoclonal antibody.
ZA928880B (en) Tumor associated monoclonal antibody 88BV59.
IE901956L (en) Monoclonal antibody.
AU8547291A (en) Monoclonal antibodies against tenascin
AU4801093A (en) Monoclonal antibodies specific for 3',6'-isold1 ganglioside

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950630

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970404

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PROTEIN DESIGN LABS, INC.

17Q First examination report despatched

Effective date: 20000407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041126